secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001404644-24-000054
Event type: earnings
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene Q1 net loss $16.9M; NGN-401 safety positive, on track for efficacy data 4Q24
--------------------------------------------------------------------------------

- Cash and investments $169.5M as of March 31, 2024; cash runway into 2H 2026.
- R&D expenses $13.5M (up 31% YoY); net loss $16.9M vs $12.3M in Q1 2023.
- NGN-401 gene therapy for Rett syndrome well-tolerated; all AEs mild/Grade 1.
- Australian regulatory clearance received; interim efficacy data from Cohort 1 expected 4Q 2024.
- Advancing early-stage pipeline; another product candidate expected to enter clinic in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000054/0001404644-24-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000054/ngne-20240510.htm
  HTML page:      https://secwatch.observer/filing/0001404644-24-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer